Published in final edited form as:

Curr Neurol Neurosci Rep. ; 17(10): 73. doi:10.1007/s11910-017-0789-z.

Molecular imaging and updated diagnostic criteria in Lewy body dementias

Nicolaas I. Bohnen, MD, PhD*, Martijn L.T.M. Müller, and Kirk A. Frey, MD, PhD

Departments of Radiology (N.I.B., M.M., K.A.F.), Neurology (N.I.B., K.A.F.), University of Michigan, and VA Ann Arbor Healthcare System (N.I.B.), Ann Arbor, MI

Abstract

Purpose of review—To review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB).

Recent findings—There do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies. PDD patients have lower cortical β -amyloid deposition than DLB. Preliminary tau PET studies suggest a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to Alzheimer disease (AD; highest). However, tau binding in DLB, including the medial temporal lobe, is substantially lower than in AD.

Summary—Alzheimer-type proteinopathies appear to be more common in DLB compared to PDD with relative but no absolute differences. Given the spectrum of overlapping pathologies, future α -synuclein ligands are expected to have best potential to distinguish the LBD from pure AD.

Keywords

Acetylcholine; β -amyloid; dementia with Lewy bodies; diagnostic criteria; dopamine; Parkinson disease with dementia; tau

*Corresponding author: N.I. Bohnen, MD, PhD; Functional Neuroimaging, Cognitive and Mobility Laboratory; University of Michigan; Domino's Farms, Lobby B, Suite 1000, Level I; 24 Frank Lloyd Wright Drive, Box 362; Ann Arbor, MI 48105-9755, USA nbohen@umich.edu.

M.L.T.M. Müller, PhD; Functional Neuroimaging, Cognitive and Mobility Laboratory; University of Michigan; Domino's Farms, Lobby B, Suite 1000, Level I; 24 Frank Lloyd Wright Drive, Box 362; Ann Arbor, MI 48105-9755, USA mtmuller@umich.edu
K.A. Frey, MD, PhD Department of Radiology, Division of Nuclear Medicine, 1500 East Medical Center Drive, Room B1-G505 UH, Ann Arbor, MI 48109-5028, USA, kfrey@umich.edu

Human Rights

All reported studies/experiments with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Disclosure No potential conflicts of interest relevant to this article were reported.

Introduction

Lewy Body dementia pathology

Parkinson disease with dementia (PDD) and dementia with Lewy bodies (DLB) together comprise the Lewy body dementias (LBD) and share a common pathological substrate of α -synucleinopathy, which is manifested by deposits in neuronal somal Lewy bodies and nerve terminal neurites [1]. Lewy body pathology has been found to be variably associated with Alzheimer disease (AD)-characteristic β -amyloid and neurofibrillary tau pathology depositions in LBD [2–7]. Furthermore, proteinopathy in subcortical projection systems may result in neurotransmitter changes, including dopaminergic and cholinergic systems, that may also contribute to cognitive impairments in LBD [8–11].

Updated clinical diagnostic criteria: PD dementia versus DLB

Lewy body dementias have a spectrum of cognitive, motor, and neurobehavioral symptoms in common. The clinical distinction of DLB and PDD is based on the temporal manifestations of cognitive and motor symptoms. This temporal difference has been operationalized using the so-called 1-year rule [12]. According to this rule, PDD is diagnosed if dementia begins after 1 year of parkinsonism and DLB if dementia begins within 1 year of the onset of parkinsonism. Recently updated criteria for PD (including associated dementia) and DLB disagree on the 1-year rule [13, 14]. The new Movement Disorder Society clinical diagnostic criteria do not consider dementia as an exclusion criterion for the diagnosis of PD, regardless of when it occurs in relation to parkinsonism onset. Patients with dementia who are already diagnosed with the DLB label can be classified as “PD dementia with Lewy bodies subtype” in the new PD diagnostic criteria [13]. In contrast, recently updated consensus diagnostic criteria for DLB uphold the 1-year rule [14]. Major changes in the updated DLB criteria include the inclusion of REM sleep behavior disorder (RBD) as a core clinical feature. Furthermore, molecular imaging biomarkers of striatal [123 I]ioflupane SPECT, dopamine transporter (DAT) and cardiac [123 I]metaiodobenzylguanidine (MIBG) sympathetic myocardial scintigraphy) are now used as indicative biomarkers. If one of these indicative biomarkers is present, only one of the four core clinical features is needed to establish a diagnosis of probable DLB [14].

It is apparent that the updated clinical diagnostic criteria for PD (dementia) and DLB are insufficient to identify and distinguish pathological mechanisms underlying the dementia syndrome. It is possible that the pathologic overlap of DLB and PDD represents confluence of separate initial pathological mechanisms at the time of emergence of dementia. Alternatively, it is conceivable that DLB and PDD represent phenotypic variations of the identical underlying disease process [15]. Furthermore, the clinical heterogeneity that can be observed among patients with either DLB or PDD may reflect distinct pathological mechanisms that may be present in some patients across both clinically defined groups, i.e., the 1-year rule may be suboptimal or even inappropriate for distinguishing subtypes of dementia pathologies in α -synucleinopathies [15].

This review will provide an overview of recent advances in molecular imaging in LBD and how these relate to the PDD and DLB subtypes based on the clinically defined 1-year rule.

Although there do not appear major differences in neurotransmitter (dopaminergic and cholinergic) systems between PDD and DLB, there is emerging evidence for relative differences in non-Lewy (β -amyloid and tau) proteinopathies between these two clinical entities.

Metabolic imaging changes in the Lewy body dementias

Prospective evaluation of [^{18}F]fluorodeoxyglucose (FDG) metabolic changes have shown that incident dementia in PD initially may present as a predominant hypometabolic posterior cortical pathology involving the visual cortex, the precuneus and posterior cingulum [16]. Subsequent progression to PDD is associated with mixed subcortical, including the caudate nuclei and the thalami, and progressive cortical changes that also include the frontal lobes [16]. In both PDD and DLB, topographic metabolic changes appear to be similar [17], including marked deficits in occipital regions. These findings emphasize the significant pathophysiological overlap between these two conditions [18].

Clinically, Alzheimer disease (AD) and DLB may also be difficult to distinguish, especially if cognitive impairment manifests before parkinsonism in DLB. Several metabolic changes, however, appear to differentiate DLB from AD. For example, bilateral medial occipital glucose hypometabolism has been associated with severity of visual hallucinations in DLB [19], and is not characteristic of AD. Relative metabolic or perfusion preservation of the mid or posterior cingulate gyrus (so-called cingulate island sign) distinguishes DLB from AD [20, 21]. Prominent manifestation of the cingulate island sign was associated with lower Braak neurofibrillary tangle stage in autopsy cases [22], which typically would be higher in AD. The presence of the cingulate island sign is also inversely associated with atrophy of the medial temporal lobe in DLB [23].

Occipital lobe hypometabolism and the cingulate sign are not specific for DLB, however, as they can also be seen with posterior cortical atrophy (PCA), a variant of AD [24]. Clinically, DLB may share some visual and visuospatial impairment with PCA. Rather than becoming more granular, however, recent diagnostic consensus criteria for PCA now allow for the diagnosis of the so-called 'PCA-plus' syndrome where patients meeting additional diagnostic criteria for either DLB or corticobasal syndrome and can be classified within the PCA disease spectrum [25]. DLB and PCA showed overlapping areas of glucose hypometabolism, including the lateral occipital lobe, lingual gyrus, precuneus, cuneus, posterior cingulate, inferior parietal lobe, supramarginal gyrus, thalamus and basal ganglia [24]. In contrast, DLB showed more severe hypometabolism in the medial occipital, anterior temporal, and orbitofrontal regions as well as the caudate nucleus than PCA. Conversely, PCA demonstrated more asymmetric hypometabolic patterns compared to DLB. The cingulate island sign was present in both PCA and DLB, although it was more asymmetric in PCA [24]. A different FDG PET study found more right-hemispheric (lateral temporo-occipital) changes in PCA versus predominant left (medial) occipital changes in DLB [26].

Neurotransmission imaging in the Lewy body dementias

Dopaminergic and cholinergic system imaging

The utility of striatal dopamine nerve terminal imaging in distinguishing DLB from AD is well established [27–29]. Dual ligand dopaminergic nerve terminal and β -amyloid imaging provides better diagnostic post-mortem confirmed classification of LBD, AD and fronto-temporal dementia compared to consensus clinical assessment [30]. Normal striatal DAT binding has been reported in autopsy-confirmed DLB [31], however, and thus cannot be an absolute exclusion criterion for this disorder.

Striatal and limbofrontal dopaminergic denervation affects specific cognitive functions in PD [32], but nigrostriatal and limbofrontal dopaminergic losses are insufficient to fully explain the presence of dementia in PD [33]. Severe cholinergic losses are a consistent finding in PDD and DLB compared to PD, and could provide an explanation for more severe cognitive impairment [33, 34]. The dual syndrome cognitive hypothesis posits that the high frequency of fronto-striatal executive changes in PD relates to dopaminergic changes, and that the emergence of dementia is associated with posterior cortical and more widespread changes secondary to additional pathologies, such as cholinergic deficits [35, 36]. In agreement with this hypothesis, we recently reported that cortical cholinergic and caudate nucleus dopaminergic deficits may contribute to cognitive decline in PD both additively and multiplicatively [37]. An imbalance of synergistic function of the cholinergic and dopaminergic transmitter systems in cognitive pathways might lead to impaired cognitive processing [38]. For example, cholinergic deficits may aggravate striatal-frontal dysfunction due to loss of compensatory cortical attentional functions, and thereby perhaps exacerbating dysfunctional cortico-striate signaling [39]. Future studies using vesicular acetylcholine transporter ligands, such as [^{18}F] FEOBV (Figure 1), may allow more precise assessment of not only cortical but also subcortical cholinergic regions in Lewy body disorders.

Cardiac sympathetic nerve terminal imaging

The autonomic nervous system is susceptible to α -synuclein pathology, which may be a mechanistic factor underlying autonomic dysfunction [40]. Severe cardiac sympathetic degeneration occurs in PD(D) or DLB, but not in AD, making it a suitable diagnostic biomarker. Indeed, recently updated diagnostic criteria for DLB provide increased diagnostic weighting to cardiac [^{123}I]MIBG noradrenergic sympathetic myocardial scintigraphy as an indicative biomarker. In these new diagnostic criteria, the presence of this biomarker abnormality in combination with only one of the clinical core features justifies a probable DLB diagnosis [14]. MIBG myocardial sympathetic imaging demonstrates good sensitivity (68.9%) and specificity (89.1%) to differentiate probable DLB from probably AD [41]. In a different study, combined use of MIBG cardiac scintigraphy and DAT SPECT imaging enabled more accurate differentiation between DLB and AD (sensitivity and specificity of 96.1% and 90.7 %, respectively) compared with either DAT SPECT or MIBG myocardial scintigraphy alone [42]. As expected there was a significantly higher frequency of motor parkinsonism in the group with abnormal dopamine nerve terminal imaging compared to those with a normal scan. Conversely, RBD was more frequently present in patients with abnormal MIBG binding compared to the normal MIBG group. These findings emphasize

the potential utility of myocardial scintigraphy in the diagnosis of LBD, especially when the differential diagnosis versus AD is difficult to make or dopamine transporter imaging findings are normal or equivocal.

Fibrillary β -amyloid PET imaging in Lewy body dementias

The putative role of β -amyloid depositions in cognitive impairment is well described in the AD literature. However, both the prevalence and the functional significance of β -amyloid depositions are less well described in LBD. A recent literature review on *in vivo* β -amyloid PET imaging findings in LBD found suggestive evidence that PD patients both without and with mild cognitive impairment (MCI) have a lower incidence of AD-range β -amyloid deposition (average 6% and 11%, respectively) compared to elderly normal subjects (average 15%), and that PDD patients have a lower incidence of β -amyloid deposition (average 27%, range 0 to 80%) than do patients with DLB (average of 57%, range 33% to 100%) [15]. A recent [^{18}F]florbetapen β -amyloid PET study confirmed these observations of very low AD-range amyloidopathy in mild PD without dementia (0/33) based on visual assessment [43]. As in AD, the degree of amyloidopathy may be modified by ApoE ϵ 4 allelegenotype status [44].

With respect to clinical manifestations of amyloidopathy in LBD, a recent review concluded inconsistent correlations between β -amyloid deposition and cognitive function, at least in cross-sectional analyses [44]. However, prospective cohort analyses have shown that precuneus amyloidopathy is associated with faster progression to cognitive impairment and dementia in PD [45, 46]. Furthermore, most *in vivo* β -amyloid PET imaging studies have focused on cortical deposition only. Neuropathological studies, however, suggest a significant role for amyloidopathy in the basal ganglia, as striatal β -amyloid deposition is significantly greater in PDD compared to PD without dementia [47–50]. We recently investigated the relative correlates of striatal and cortical β -amyloid deposition to cognitive impairment in PD subjects with risk factors for PDD, such as older age, postural imbalance, or cognitive changes [51]. Elevated striatal amyloidopathy was present in about half of the patients with concomitant increased cortical binding. We found significantly lower cognitive performance in subjects with combined cortical and striatal β -amyloid deposition compared to those with abnormal cortical binding only. These findings suggest that amyloidopathy, especially in the striatum, may play a role in cognitive impairment in the LBD. Future studies investigating the role of amyloidopathy in cognitive impairment in LBD should include striatal regions.

Tau PET imaging in Lewy body dementias

Tau proteinopathies are becoming an important imaging target in LBD. A [^{18}F]AV-1451 tau PET imaging study in a small number of 7 DLB patients found that AV-1451 uptake was mildly increased in the inferolateral temporal and parietal/precuneus regions compared to control subjects [52]. Greater AV-1451 uptake in the inferior temporal gyrus and precuneus in a combined group of DLB and cognitively impaired PD patients was associated with increased cognitive impairment as measured with the mini-mental state examination (MMSE) and the Clinical Dementia Rating scale [52]. Shorter duration of disease was

associated with greater AV-1451 uptake in the inferior temporal gyrus and precuneus in the DLB group. A subsequent larger [^{18}F]AV-1451 tau PET imaging study found that AV-1451 uptake was substantially more severe and extensive in AD compared to DLB patients [53]. Medial temporal uptake completely distinguished AD dementia (highest) from probable DLB (lowest). Probable DLB patients had higher inferior, middle, and superior occipital, lingual, angular, fusiform, middle and inferior temporal gyri, and precuneus and cuneus AV-1451 uptake compared to normal control subjects [53]. These investigators did not find, however, a significant correlation between posterior temporo-parietal and occipital AV-1451 uptake and clinical measures, including cognition, visual hallucinations, motor parkinsonism or presence of RBD. Higher [^{11}C]PIB β -amyloid binding was associated with higher AV-1451 uptake in these regions suggesting an atypical pattern of tau deposition in probable DLB patients [53]. Overall, there appears to be a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to AD (highest); Table 1 [52, 54].

Neuroinflammation imaging in the Lewy body dementias

Neuroinflammation may be a key factor in the pathogenesis of dementing disorders, including LBD [55]. PET markers of mitochondrial translocator protein (TSPO) expression, performed initially with [^{11}C]PK11195, can be used for the *in vivo* assessment of microglial and astrocytic activation. Glial activation was shown in the putamen and substantia nigra in both DLB and PD patients using [^{11}C]PK11195 PET [56]. In contrast, DLB patients also showed increased uptake in the caudate and an extended glial activation pattern in several cortical regions and the cerebellum, suggesting possible evidence of a disease propagation pattern [56]. In PDD glial activation (using [^{11}C]PK11195 PET) was observed in the anterior and posterior cingulate, striatum and frontal, temporal, parietal, and occipital cortical regions [57]. Increased tracer binding was more extensive in PDD compared to PD. There was also a significant correlation between cognitive scores (MMSE) and glial activation, suggesting that microglial or astrocytic activation may be associated with neuronal damage in PDD [57]. Multi-modal imaging studies have found inconsistent relationships between the extent of glial activation and glucose metabolic or amyloidopathy changes in LBD [56–59].

Significant glial activation may be a factor in driving the disease process in LBD. It should be noted, however, that neuroinflammatory mechanisms are complex and not well understood, and inflammation could also be neuroprotective under certain conditions and stages of the neurodegenerative process [60]. Novel neuroinflammation imaging techniques, based on next generation radiotracer probes, may be better able to disentangle the effects of inflammation in different stages of the neurodegenerative processes as they relate to clinical deterioration and may help in development of more effective interventions [61].

Discussion

Proteinopathy and neurotransmitter changes in the Lewy body dementias: Incremental and threshold effects?

Combined multi-ligand PET analysis in PD patients who were recruited based on risk factors for PDD (older age, imbalance, cognitive changes) showed evidence of independent cognitive contributions of not only individual neurotransmitter changes (dopamine, acetylcholine) but also β -amyloidopathy [51]. Triple-ligand analysis showed that global composite cognitive z-scores were best predicted by cortical cholinergic activity and global (cortical and striatal) β -amyloid binding. Verbal learning cognitive domain z-scores were predicted by cortical β -amyloid and cortical cholinergic activity. Attention cognitive domain z-scores were predicted by striatal β -amyloid uptake and caudate nucleus dopaminergic activity. Executive functions cognitive domain scores were predicted by cortical cholinergic activity [51]. These data provide supportive evidence that neurotransmitter and proteinopathy changes have independent and incremental contributions to cognitive impairment in PD at risk of PDD. Likewise, variable presence and combinations of proteinopathies and neurotransmitter changes may define endophenotypes within the cognitive impairment syndrome of the LBD [62].

We reported previously that even low levels of cortical β -amyloidopathy associated with cognitive changes in PD patients at risk of dementia [63]. Interestingly, a number of cognitively normal elderly subjects in our study manifested higher levels of amyloidopathy than observed in our PD population. This suggests that, along with the observation that subjects with AD have a much higher amyloidopathy threshold to manifest cognitive changes, there may be a lower threshold for manifestation of β -amyloid associated cognitive impairment in PD [15]. In PD, however, β -amyloid deposition occurs in the setting of Lewy proteinopathy and multiple neurotransmitter system changes. The presence of multiple pathologies in PD likely reduces the cerebral capacity to adapt to additional β -amyloid burden and thereby may lower its symptomatic threshold for cognitive or clinical symptom manifestation of this proteinopathy. This is in keeping with accumulating post-mortem evidence, which indicates that the presence of two proteinopathies (α -synucleinopathy and β -amyloidopathy) in PDD may exert additive or even synergistic detrimental interactions [64]. For example, comorbid cerebral β -amyloidopathy in PDD is associated with more severe clinical outcome, faster conversion to dementia, and shorter survival compared to PDD patients with more "pure" Lewy body pathology [5, 65]. It is conceivable that the presence of tau proteinopathy also may become symptomatic at low levels in the setting of multiple pathologies in LBD, but further studies are needed to confirm this hypothesis.

Imaging of brain network disruption in the Lewy body dementias

Pathological and neurotransmitter system changes ultimately affect brain networks in PD [66–68]. Spatial covariance mapping has shown a distinct PD cognition-related network pattern (PDCP) characterized by FDG metabolic reductions in the parietal association, medial prefrontal, and premotor regions, with relative increases in the dentate nuclei and vermis [69]. Interestingly, PDCP expression was correlated with more severe losses of dopamine transporters in the caudate nucleus [70] and greater executive function rather than

memory deficits [71]. Furthermore, PDCP network is largely spatially and functionally distinct from metabolic network changes seen in AD [71]. Spatial covariance mapping of regional cerebral perfusion changes using [^{99m}Tc]HMPAO SPECT in DLB found evidence of a cognitive-motor network pattern characterized by bilateral relative increases in the striatum, cerebellum, and supplementary motor areas and widespread bilateral reductions in parietal areas [72]. Interestingly, this perfusion pattern correlated with poorer cognitive performance, including attention, and fluctuations in cognitions.

Apart from dopaminergic modulation of cerebral networks there is also evidence of cholinergic network modulation in PDD. An M1/M4 subtype muscarinic receptor brain SPECT study using the [¹²³I]QNB ligand found evidence of decreasing binding in basal forebrain, temporal cortex, striatum, insula and anterior cingulum in PDD, implicating decreased signal detection capacity in limbic-paralimbic and salience cholinergic networks [73]. Regional cerebral blood flow findings using [^{99m}Tc] exametazime SPECT in these patients demonstrated relative hypoperfusion in temporoparietal and prefrontal cortical regions and nodes of the frontoparietal and default mode networks. The muscarinic receptor pattern that correlated with cognitive improvement after donepezil administration coincided with the default mode network and frontoparietal networks [73]. These findings provide supportive evidence for the presence of several dysfunctional cholinergic networks in PDD. Collectively, these data show the presence of functional cognitive brain networks that can be altered in PDD or DLB and may be modulated by dopaminergic or cholinergic neurotransmitter changes.

Differential molecular imaging diagnostic approaches to distinguish LBD from AD: Are we ignoring the presence of overlapping pathologies?

Molecular imaging studies have shown the utility of distinguishing LBD from AD based on dopaminergic nerve terminal imaging with good diagnostic accuracy [30, 74]. However, a normal pattern of striatal dopamine nerve terminal activity is insufficient to exclude LBD as a small number of subjects may have normal uptake [31]. This may be of particular relevance in the absence of motor parkinsonism. Cardiac sympathetic nerve terminal imaging is now defined as an indicative biomarker to distinguish DLB from AD [14] but studies also show the presence of subsets of patients with normal cardiac sympathetic nerve terminals [42, 72]. Hence, a normal cardiac sympathetic nerve terminal scan does not fully exclude DLB.

Proteinopathy imaging studies confirm the spectrum nature of overlapping pathologies in neurodegenerative disorders [52, 53, 72]. Recent FDG PET imaging studies also demonstrate overlapping metabolic changes between DLB and the PCA variant of AD [24]. These observations suggest that attempts to distinguish neurodegenerative disorders based on their clinical phenotype may ignore shared pathobiological mechanisms. Ultimately, it may be expected that with the introduction of novel molecular therapeutics in the clinic, imaging biomarkers that have specific binding to such therapeutic targets will be used for the identification of a specific pathobiology (and subsequent monitoring of treatment response) rather than establishing a clinically defined diagnostic entity.

Conclusions

Although Lewy bodies or neurites are the primary pathology, the etiology of cognitive decline in LBD is heterogeneous. Molecular imaging studies in LBD have targeted neurotransmitter systems, non-Lewy proteinopathies, and glucose metabolic or perfusion changes. Metabolic changes appear to show similar topographic changes in both DLB and PDD, including marked deficits in occipital regions and relative sparing of the medial temporal lobe compared to AD confirming the significant overlap between these two clinical conditions. Nigrostriatal denervation is another shared pathophysiology of LBD though normal striatal dopamine nerve terminal activity can occasionally be seen in DLB.

More recent studies highlight the role of Alzheimer proteinopathies, including β -amyloid and tau, where there is increasing evidence of relative differences between DLB and PDD. PDD patients have a lower incidence of cortical β -amyloid deposition (average 27%) than do patients with DLB (average of 57%). Striatal amyloidopathy may be a critical driver of cognitive impairment rather than isolated cortical deposition, at least in PD at risk of dementia. Tau PET studies demonstrate significantly lower uptake in DLB compared to AD, but higher than in PD(D). In particular medial temporal uptake in DLB was below the lower range of uptake seen in AD and could be used as discriminatory marker.

Molecular imaging studies confirm the heterogeneous etiology underlying the cognitive impairment syndrome in LBD, where neurotransmitter and proteinopathy changes may have incremental and possibly interactive effects. Variable presence and combinations of proteinopathies and neurotransmitter changes may define endophenotypes within the cognitive impairment syndrome of LBD. Future molecular imaging studies targeting α -synuclein proteinaceous deposits are expected to shed further insights in the pathogenesis of LBD. As there is increasing recognition of a spectrum of overlapping pathobiology, future molecular imaging studies may shift away from providing diagnostic biomarkers for clinically defined entities. Rather, molecular imaging may identify the presence of specific molecular pathologies and may play an increasingly important role in guiding treatment of neurodegenerative disorders rather than establishing a clinical diagnosis.

Acknowledgments

The presented research data from the authors' work was supported by grants from the NIH [P01 NS015655, RO1 NS070856, with additional support from P50 NS091856], Department of Veterans Affairs [I01 RX000317] and the Michael J. Fox Foundation.

Abbreviations

AD	Alzheimer disease
DLB	dementia with Lewy bodies
DAT	dopamine transporter
FDG	fluorodeoxyglucose
MCI	mild cognitive impairment

MIBG	metaiodobenzylguanidine
MMSE	mini-mental state examination
PCA	posterior cortical atrophy
PD	Parkinson disease
PDD	Parkinson disease with dementia
RBD	REM sleep behavior disorder

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance

- Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. *Acta Neuropathol.* 2001; 102:355–63. [PubMed: 11603811]
- Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. *Acta Neuropathol.* 2008; 115:427–36. [PubMed: 18273624]
- Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, Hortobagyi T, Francis PT. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. *Brain Pathol.* 2015; 25:401–8. [PubMed: 25103200]
- Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, Lees AJ, Revesz T. The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson's disease progression and related dementia. *Neurodegener Dis.* 2014; 13:154–156. [PubMed: 24028925]
- Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS. Pathologic Accumulation of alpha-Synuclein and Abeta in Parkinson Disease Patients With Dementia. *Arch Neurol.* 2012; 69:1–6.
- Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ. Neuropathologic substrates of Parkinson disease dementia. *Ann Neurol.* 2012; 72:587–98. [PubMed: 23037886]
- Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, Lee EB, Arnold SE, Duda JE, Hurtig H, Lee VM, Adler CH, Beach TG, Trojanowski JQ. Pathological alpha-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. *Acta Neuropathol.* 2016; 131:393–409. [PubMed: 26721587]
- Gaspar P, Gray F. Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases. *Acta Neuropathol (Berl).* 1984; 64:43–52. [PubMed: 6089493]
- Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. *Proc Natl Acad Sci U S A.* 1987; 84:5976–80. [PubMed: 3475716]
- Jellinger KA. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? *J Neural Transm Suppl.* 1999; 56:1–29. [PubMed: 10370901]
- Kalaitzakis ME, Pearce RK. The morbid anatomy of dementia in Parkinson's disease. *Acta Neuropathol.* 2009; 118:587–98. [PubMed: 19820956]
- McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guideline for the clinical and pathological diagnosis of dementia with Lewy bodies (LBD): report of the Consortium on DLB International Workshop. *Neurology.* 1996; 47:1113–1124. [PubMed: 8909416]

13. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015; 30:1591–601. [PubMed: 26474316]
14. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017; 89:88–100. [PubMed: 28592453]
15. Frey KA, Petrou M. Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. *Clinical and translational imaging*. 2015; 3:57–64. [PubMed: 25745616]
16. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. *J Nucl Med*. 2011; 52:848–55. [PubMed: 21571793]
17. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. *Ann Neurol*. 2001; 50:358–365. [PubMed: 11558792]
18. Granert O, Drzezga AE, Boecker H, Perneczky R, Kurz A, Gotz J, van Eimeren T, Haussermann P. Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits. *J Nucl Med*. 2015; 56:1916–21. [PubMed: 26383147]
19. Firbank MJ, Lloyd J, O'Brien JT. The relationship between hallucinations and FDG-PET in dementia with Lewy bodies. *Brain imaging and behavior*. 2016; 10:636–9. [PubMed: 26239998]
20. Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, Bradshaw J, Merory J, Woodward M, Hopwood M, Rowe CC. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. *J Nucl Med*. 2009; 50:1638–45. [PubMed: 19759102]
21. Imabayashi E, Yokoyama K, Tsukamoto T, Sone D, Sumida K, Kimura Y, Sato N, Murata M, Matsuda H. The cingulate island sign within early Alzheimer's disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer's disease from dementia with Lewy bodies. *EJNMMI research*. 2016; 6:67. [PubMed: 27620458]
- *22. Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, Lesnick TG, Senjem ML, Gunter JL, Smith GE, Knopman DS, Jack CR Jr, Dickson DW, Petersen RC, Kantarci K. Dementia with Lewy bodies: basis of cingulate island sign. *Neurology*. 2014; 83:801–9. Study showing evidence of neuropathological correlate of the cingulate island sign in DLB. [PubMed: 25056580]
23. Iizuka T, Kameyama M. Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies. *Ann Nucl Med*. 2016; 30:421–9. [PubMed: 27098829]
- *24. Whitwell JL, Graff-Radford J, Singh TD, Drubach DA, Senjem ML, Spychalla AJ, Tosakulwong N, Lowe VJ, Josephs KA. ¹⁸F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. *J Nucl Med*. 2017; 58:632–638. Comprehensive study comparing FDG metabolic difference and overlap between PCA and DLB. [PubMed: 27688479]
25. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff-Radford J, Graff-Radford NR, Hof PR, Krolak-Salmon P, Lehmann M, Magnin E, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Pijnenburg Y, Primativo S, Rossor MN, Ryan NS, Scheltens P, Shakespeare TJ, Suarez Gonzalez A, Tang-Wai DF, Yong KX, Carrillo M, Fox NC. Alzheimer's Association, IAAsD, Associated Syndromes Professional Interest, A. Consensus classification of posterior cortical atrophy. *Alzheimers Dement*. 2017

26. Spehl TS, Hellwig S, Amtage F, Weiller C, Bormann T, Weber WA, Hull M, Meyer PT, Frings L. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study. *J Neuroimaging*. 2015; 25:281–8. [PubMed: 24593796]
27. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. *J Neurol Neurosurg Psychiatry*. 2007; 78:1176–81. [PubMed: 17353255]
28. McKeith I, O'Brien J, Walker Z, Tatsch K, Booi J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reiningner C, Group DLBS. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *Lancet Neurol*. 2007; 6:305–13. [PubMed: 17362834]
29. Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. *Alzheimers Dement*. 2008; 4:S67–76. [PubMed: 18632004]
30. Albin RL, Fisher-Hubbard A, Shanmugasundaram K, Koeppe RA, Burke JF, Camelo-Piragua S, Lieberman AP, Giordani B, Frey KA. Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications. *Ann Neurol*. 2015; 78:824–30. [PubMed: 26183692]
31. Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. *Brain*. 2012; 135:2798–808. [PubMed: 22961551]
32. Christopher L, Marras C, Duff-Canning S, Koshimori Y, Chen R, Boileau I, Segura B, Monchi O, Lang AE, Rusjan P, Houle S, Strafella AP. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. *Brain*. 2014; 137:565–75. [PubMed: 24334314]
33. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, Hilker R. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. *Neurology*. 2010; 74:885–92. [PubMed: 20181924]
34. Bohnen NI, Kaufer DI, Ivancu LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. *Arch Neurol*. 2003; 60:1745–8. [PubMed: 14676050]
35. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. *Brain*. 2007; 130:1787–98. [PubMed: 17535834]
36. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. *Neurodegener Dis*. 2013; 11:79–92. [PubMed: 23038420]
37. Bohnen NI, Albin RL, Muller ML, Petrou M, Kotagal V, Koeppe RA, Scott PJ, Frey KA. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. *JAMA Neurol*. 2015; 72:194–200. [PubMed: 25506674]
38. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. *Lancet Neurol*. 2006; 5:974–83. [PubMed: 17052664]
39. Sarter M, Albin RL, Kucinski A, Lustig C. Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. *Exp Neurol*. 2014; 257C:120–129.
40. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. *Brain*. 2008; 131:642–50. [PubMed: 18079166]
41. Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, Hanyu H, Iizuka O, Iseki E, Kashiwara K, Kosaka K, Maruno H, Mizukami K, Mizuno Y, Mori E, Nakajima K, Nakamura H, Nakano S, Nakashima K, Nishio Y, Orimo S, Samuraki M, Takahashi A, Taki J, Tokuda T, Urakami K, Utsumi K, Wada K, Washimi Y, Yamasaki J, Yamashina S, Yamada M. Diagnostic accuracy of

- ¹²³I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. *PLoS One*. 2015; 10:e0120540. [PubMed: 25793585]
42. Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D, Fukasawa R, Umahara T, Sakurai H, Hanyu H. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2016; 43:184–92. [PubMed: 26233438]
 43. Mashima K, Ito D, Kameyama M, Osada T, Tabuchi H, Nihei Y, Yoshizaki T, Noguchi E, Tanikawa M, Iizuka T, Date Y, Ogata Y, Nakahara T, Iwabuchi Y, Jinzaki M, Murakami K, Suzuki N. Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia. *Eur Neurol*. 2017; 77:231–237. [PubMed: 28285306]
 44. Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET Imaging in Lewy body disorders. *Am J Geriatr Psychiatry*. 2015; 23:23–37. [PubMed: 23831180]
 45. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. *Neurology*. 2013; 80:85–91. [PubMed: 23243071]
 46. Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH. PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. *Neurodegener Dis*. 2016; 16:118–24. [PubMed: 26655867]
 47. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta-amyloid deposition in Parkinson disease with dementia. *J Neuropathol Exp Neurol*. 2008; 67:155–61. [PubMed: 18219254]
 48. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. *J Neural Transm*. 2011; 118:713–9. [PubMed: 21479514]
 49. Dugger BN, Serrano GE, Sue LI, Walker DG, Adler CH, Shill HA, Sabbagh MN, Caviness JN, Hidalgo J, Saxon-Labelle M, Chiarolanza G, Mariner M, Henry-Watson J, Beach TG. the Arizona Parkinson's Disease C. Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. *Journal of Parkinson's disease*. 2012; 2:57–65.
 50. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes. *Neurobiol Dis*. 2011; 41:377–84. [PubMed: 20951207]
 51. Shah N, Frey KA, MLTMM, Petrou M, Kotagal V, Koeppe RA, Scott PJ, Albin RL, Bohnen NI. Striatal and Cortical beta- Amyloidopathy and Cognition in Parkinson's Disease. *Mov Disord*. 2016; 31:111–7. [PubMed: 26380951]
 - *52. Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, Sperling R, Growdon JH, Dickerson BC, Johnson K. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. *JAMA Neurol*. 2016; 73:1334–1341. Study showing evidence of cognitive correlates of in vivo tau imaging in Lewy body patients. [PubMed: 27654968]
 - **53. Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG, Spychalla AJ, Gunter JL, Fields JA, Graff-Radford J, Ferman TJ, Jones DT, Murray ME, Knopman DS, Jack CR Jr, Petersen RC. AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. *Ann Neurol*. 2017; 81:58–67. This multi-modal imaging study is the largest study to date showing the spectrum of tau pathology between AD, DLB and control subjects. [PubMed: 27863444]
 54. Hansen AK, Damholdt MF, Fedorova TD, Knudsen K, Parbo P, Ismail R, Ostergaard K, Brooks DJ, Borghammer P. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. *Mov Disord*. 2017; 32:922–927. [PubMed: 28256006]
 55. Mrak RE, Griffin WS. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. *J Neuropathol Exp Neurol*. 2007; 66:683–6. [PubMed: 17882012]
 56. Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, Gelsomino G, Moresco RM, Perani D. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. *Parkinsonism Relat Disord*. 2013; 19:47–52. [PubMed: 22841687]

57. Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, Walker Z, Turkheimer FE, Brooks DJ. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. *Neuropsychopharmacology*. 2013; 38:938–49. [PubMed: 23303049]
58. Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, Brooks DJ, Edison P. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. *Alzheimers Dement*. 2015; 11:608–21. e7. [PubMed: 25239737]
59. Femminella GD, Ninan S, Atkinson R, Fan Z, Brooks DJ, Edison P. Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia? *J Alzheimers Dis*. 2016; 51:1275–89. [PubMed: 27060942]
60. Stefaniak J, O'Brien J. Imaging of neuroinflammation in dementia: a review. *J Neurol Neurosurg Psychiatry*. 2016; 87:21–8. [PubMed: 26384512]
61. Varley J, Brooks DJ, Edison P. Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. *Alzheimers Dement*. 2015; 11:1110–20. [PubMed: 25449529]
62. Modreanu R, Cerquera SC, Marti MJ, Rios J, Sanchez-Gomez A, Camara A, Fernandez M, Compta Y. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal tau and Abeta as well as dementia-risk in Parkinson's disease. *J Neurol Sci*. 2017; 373:223–229. [PubMed: 28131192]
63. Petrou M, Bohnen NI, Muller ML, Koeppe RA, Albin RL, Frey KA. Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. *Neurology*. 2012; 79:1161–7. [PubMed: 22933741]
64. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. *PLoS One*. 2008; 3:e3135. [PubMed: 18769546]
65. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovceva J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? *Brain*. 2011; 134:1493–505. [PubMed: 21596773]
66. Lebedev AV, Westman E, Simmons A, Lebedeva A, Siepel FJ, Pereira JB, Aarsland D. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. *Frontiers in systems neuroscience*. 2014; 8:45. [PubMed: 24765065]
67. Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. *Brain*. 2015; 138:1454–76. [PubMed: 25888551]
68. Caminiti SP, Tettamanti M, Sala A, Presotto L, Iannaccone S, Cappa SF, Magnani G, Perani D. Alzheimer's Disease Neuroimaging I. Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. *J Cereb Blood Flow Metab*. 2017; 37:1311–1325. [PubMed: 27306756]
69. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. *Ann Neurol*. 2012; 72:635–47. [PubMed: 22941893]
70. Niethammer M, Tang CC, Ma Y, Mattis PJ, Ko JH, Dhawan V, Eidelberg D. Parkinson's disease cognitive network correlates with caudate dopamine. *Neuroimage*. 2013; 78:204–9. [PubMed: 23578575]
71. Mattis PJ, Niethammer M, Sako W, Tang CC, Nazem A, Gordon ML, Brandt V, Dhawan V, Eidelberg D. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. *Neurology*. 2016; 87:1925–1933. [PubMed: 27708130]
72. Taylor JP, Colloby SJ, McKeith IG, O'Brien JT. Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in dementia with Lewy bodies. *Int Psychogeriatr*. 2013; 25:1917–28. [PubMed: 24148774]
73. Colloby SJ, McKeith IG, Burn DJ, Wyper DJ, O'Brien JT, Taylor JP. Cholinergic and perfusion brain networks in Parkinson disease dementia. *Neurology*. 2016; 87:178–85. [PubMed: 27306636]
74. Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. *Brain*. 2011; 134:1647–57. [PubMed: 21555336]

Figure 1. $[^{18}\text{F}]$ FEOBV vesicular acetylcholine transporter images in patients with DLB (n=4, upper row) and healthy controls (n=7, lower row). Prominent reductions in neocortical, archicortical (hippocampus) and subcortical structures (basal ganglia, thalamus) are present in DLB compared to normal control subjects. Figure courtesy of Robert Koeppe, PhD.

In vivo tau PET imaging studies in PD (cognitive impairment), DLB and AD. Findings suggest a gradient of increasing tau binding from cognitively normal PD (absent to lowest) to cognitively impaired PD (low) to DLB (intermediate) to AD (highest).

Table 1

Ligand	Study population	Major findings
¹⁸ F]AV-1451 tau PET (Hansen et al. 2017)	PD (n=26) without or with mild cognitive impairment; healthy controls (n=23)	Tau pathology, as detected by AV-1451, is uncommon in PD with mild cognitive impairment and shows no significant correlation with cognitive dysfunction at this stage.
¹⁸ F]AV-1451 tau PET (Gomperts et al. 2016)	DLB (n=7) and PD cognitively impaired (n=8) or cognitively normal (n=9)	AV-1451 uptake was mildly increased in the inferolateral temporal and parietal/precuneus regions compared to control subjects. Greater AV-1451 uptake in the inferior temporal gyrus and precuneus in a combined group of DLB and cognitively impaired PD patients was associated with increased cognitive impairment as measured with the MMSE and the Clinical Dementia Rating scale. Shorter duration of disease was associated with greater AV-1451 uptake in the inferior temporal gyrus and precuneus in the DLB group.
¹⁸ F]AV-1451 tau PET (Kantarci et al. 2017)	AD (n=18); DLB (n=15); controls (n=90)	AV-1451 uptake was more severe and extensive in AD compared to DLB patients. Medial temporal uptake completely distinguished AD dementia from probable DLB. Probable DLB patients had higher inferior, middle, and superior occipital, lingual, angular, fusiform, middle and inferior temporal gyri, and precuneus and cuneus AV-1451 uptake compared to normal control subjects. No significant cognitive or clinical correlations of AV-1451 binding.